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Lowering LDL cholesterol with statins clearly reduces 
the risk of cardiovascular events among individuals 
at increased cardiovascular risk, and is a mainstay of 
contemporary approaches to cardiovascular disease 
prevention. Chronic kidney disease  is a well established 
independent risk factor for cardiovascular events, but 
guidelines vary in their approach to lipid-lowering in 
this population. The European Society of Cardiology/
European Atherosclerosis Society (ESC/EAS) guidelines 
suggest that chronic kidney disease is an indication 
for statin therapy, whereas the American College 
of Cardiology (ACC)/American Heart Association 
(AHA) guidelines do not.1 The KDIGO (Kidney Disease: 
Improving Global Outcomes) guidelines recommend 
guidelines have been developed to assist researchers 
working in this ﬁ eld.6 Existing analysis of usage data 
has led to concepts such as non-use attrition7 and 
intervention adherence8 that have allowed much better 
understanding of intervention eﬃ  cacy and avenues 
to improve potency of web-based interventions. For 
example, in a large web-based trial,9 we witnessed 
weight loss results simultaneously with poor initial 
retention and poor uptake of speciﬁ c website features. 
With analysis of intervention data, we were able to 
understand key website features that predict weight 
loss in order to improve future interventions. During 
piloting of the initial POWeR intervention, usage metrics 
were also analysed in great depth,10 yet no such data 
are reported in the present study. Not all usage data 
need to be explored this deeply, and simple data can 
still oﬀ er insight into intervention adherence, uptake, 
and exposure without diluting evaluation of primary 
outcomes or alienating speciﬁ c readerships, when 
reported appropriately.4 
Future studies should aspire to incorporate excellent 
translational strategies and rigorous research methods 
such as those used by Little and colleagues, but they also 
need to unlock the black box so interventions can rise to 
the challenge of long-term weight maintenance.11 Some 
ﬁ ndings have suggested that technology can provide 
only a transient eﬀ ect12 and that face-to-face contact 
might be the answer to longer term maintenance 
of weight loss.13 Carefully developed, integrated 
interventions such as POWeR+ might be able to 
overcome these limitations. However, an intervention’s 
true eﬃ  cacy will only be fully understood when we can 
ensure that participants are receiving the intended 
intervention dose. This is particularly the case when 
eHealth components are integral to an intervention 
because user engagement could be a crucial moderator 
of success.
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that lipid-lowering should not be initiated in adults 
with dialysis-dependent chronic kidney disease, but 
should be continued in patients already receiving such 
treatment at the time of dialysis initiation.2
Several reviews in this area have generally concluded 
that lipid-lowering is beneﬁ cial in early-stage chronic 
kidney disease, but results in advanced disease diﬀ er.3,4 
Inevitably, the limitations of literature-based systematic 
reviews amplify the uncertainty in this patient population.
In The Lancet Diabetes & Endocrinology, the Cholesterol 
Treatment Trialists’ (CTT) Collaboration report the 
results of a prespeciﬁ ed meta-analysis of 28 randomised 
control trials assessing the eﬀ ects of LDL cholesterol 
reduction with statins according to baseline renal 
function.5 As well as having access to individual 
participant data from all the trials, the investigators 
were also able to reclassify outcomes in one of the key 
trials (AURORA) to improve assessment consistency, 
and to standardise the results to the degree of LDL 
cholesterol lowering achieved. These approaches reduce 
some of the potential sources of noise and uncertainty 
when trial data are pooled. 
The CTT Collaboration reports that, overall, statin-
based therapy reduced the risk of a ﬁ rst major vascular 
event by 21% per 1·0 mmol/L reduction in LDL 
cholesterol (rate ratio [RR] 0·79, 95% CI 0·77–0·81; 
p<0·0001). Smaller relative eﬀ ects on major vascular 
events were recorded as estimated glomerular ﬁ ltration 
rate (eGFR) declined (p=0·008 for trend). The results 
provide convincing evidence that statin therapy is 
beneﬁ cial in a wide range of patients with chronic 
kidney disease, with beneﬁ ts proportional to the 
absolute LDL cholesterol reduction achieved. They also 
provide further evidence that the relative risk reductions 
achieved for major cardiovascular events diminish in 
magnitude with reducing kidney function.3,4
In people with end-stage kidney disease, the eﬀ ects 
of statins were uncertain, with no clear beneﬁ ts shown 
(RR 0·94, 99% CI 0·79–1·11 for patients on dialysis).5 
Importantly, although the magnitude of the relative risk 
reduction was less with reducing kidney function, the 
increasing cardiovascular risk observed in people with 
reduced kidney function (for major coronary events, 
p=0·01 for trend; for vascular mortality, p=0·03 for 
trend), means that the absolute risk reductions (and the 
resultant number needed to treat [NNT] to prevent an 
event) are potentially similar. For example, the Study of 
Heart And Renal Protection (SHARP)6 included people 
with chronic kidney disease, including a substantial 
number who needed dialysis, and showed an absolute 
risk reduction among participants receiving dialysis of 
1·5%, compared with 2·4% for those with earlier stage 
chronic kidney disease (ﬁ gure), resulting in NNTs of 
67 and 42, respectively. Therefore, it is unclear whether 
the statistically uncertain, smaller relative risk reductions 
in patients with end-stage kidney disease result from 
a true lack of eﬃ  cacy of statins in these individuals, or 
whether a similar reduction in risk attributable to statin 
therapy is not detectable, owing to reduced power 
associated with event diﬀ erences being drowned out by 
a larger number of less statin-sensitive cardiovascular 
events such as arrhythmias and heart failure. 
How do we move forward? Although large clinical 
trials in individuals with advanced chronic kidney 
disease can be challenging because of diﬃ  culties with 
recruitment, retention, tolerability, comorbidities, 
and other factors, they have proven feasible and are 
very important because of the high cardiovascular 
risk and disease burden in this population. Promising 
new treatments (eg, PCSK9 inhibitors) are eﬀ ective 
at lowering LDL cholesterol, and early results of 
randomised trials suggest they might reduce the risk 
of cardiovascular events substantially.7 Studies of these 
agents in people with advanced kidney disease could, 
therefore, be especially important, for assessing whether 
they signiﬁ cantly reduce the substantially increased risk 
of cardiovascular disease in this population. 
An additional important consideration is the eﬀ ect of 
statin therapy on kidney function in people with chronic 
Figure: Cardiovascular event rates prevented (absolute diﬀ erence between 
randomised groups) and not prevented (residual event rates in the statin 
arm) in the SHARP trial,6 according to baseline renal function
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kidney disease. A combined analysis from the PLANET 
studies8 showed that individuals randomly assigned to 
atorvastatin not only had lower levels of proteinuria at 
the end of the 12-month study but also had signiﬁ cantly 
slower decline in kidney function. Findings of other 
studies have suggested that at least some statins might 
have beneﬁ cial eﬀ ects on kidney function.8,9 Although 
eﬀ ects on kidney function were not assessed in the CTT 
Collaboration’s current meta-analysis, it is an important 
topic worthy of more detailed analysis, and ideally 
suited to the CTT Collaboration’s datasets, and perhaps 
studies of PCSK9 inhibitors. 
Although the results from this CTT Collaboration 
meta-analysis provide clear evidence of the role of 
statins in chronic kidney disease, they raise further 
questions about the eﬀ ects of lipid-lowering in 
advanced disease and highlight the importance of new 
trials with highly eﬀ ective agents in this population. 
By deﬁ ning what we still do not know, this analysis 
will hopefully encourage further studies that improve 
outcomes for this high-risk patient group. 
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Cardiac natriuretic peptides in plasma: from prediction to 
precision medicine
In The Lancet Diabetes and Endocrinology, the Natriuretic 
Peptides Study Collaboration1 show plasma measurement 
of the cardiac hormone N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) to be predictive not only of 
coming coronary heart disease, but also future stroke 
in individuals without known cardiovascular disease at 
the time of measurement (risk ratio for combination 
of coronary heart disease and stroke 1·76 [95% CI 
1·56–1·98]). The individual-participant-data meta-
analysis included 40 prospective cohorts comprising 
over 95 000 individuals and is thus the largest study 
of its kind of NT-proBNP measurement in plasma. 
The authors conclude that addition of NT-proBNP 
measurements to conventional risk assessment in people 
without cardiovascular disease might improve accuracy 
in cardiovascular and stroke risk prediction, which means 
that some individuals at increased risk might be identiﬁ ed 
for possible therapeutic or lifestyle interventions.
Measurement of cardiac natriuretic hormones and 
their precursors in plasma has mostly been a matter of 
congestive heart failure. Today, plasma measurement is 
included in all high-income country guidelines for heart 
failure assessment, for which the natriuretic hormones 
and prohormones best serve to rule out the presence 
of congestive heart failure. Strikingly, this use basically 
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